Compare Davita Inc (DVA) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Spotify Technology — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Spotify Technology trades at $526.49 (market cap $105.45B). The key difference: Spotify Technology is far larger — about 9.3× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Spotify Technology for 111 Days on average.
| DVA | SPOT | |
|---|---|---|
Market Cap | $11.28B | $105.45B |
Volume | 650,294 | 2,000,851 |
Sector | Health | Media |
52-Week High | $240.96 | $692.04 |
52-Week Low | $103.87 | $412.75 |
Typical Hold Time | 113 Days | 111 Days |
Enterprise Value | $24.00B | $95.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Spotify (SPOT) trades at $526.42, up 7.84% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with revenue growth from $15.7B to $17.2B in 2025 and net income surging to $2.2B. Recent Q2 2026 earnings missed expectations, but analyst consensus remains strongly bullish with a $610 price target. Technical indicators show support at $497 and resistance at $524, with the stock approaching key resistance levels.
Spotify presents a compelling growth story with expanding profit margins and strong cash flow generation. The primary investment opportunity lies in continued subscriber growth and margin expansion, though risks include competitive pressures in streaming and execution challenges. Wall Street maintains strong conviction with 62% buy ratings, suggesting 16% upside to consensus targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
